Navigation Links
Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
Date:10/27/2008

st in their review of Abaxis' performance relative to prior periods and its competitors.

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in our conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks associated with liquidity concerns related to our auction rate securities, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, predictions related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables on Following Pages

ABAXIS, I
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
2. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
9. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
10. Aware, Inc. Reports Third Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Last week, Representatives Gus Bilirakis (R-FL) ... bold bipartisan step on behalf of patients with ... co-sponsors of the legislation include Representatives McCaul (R-TX) ... makers and innovators to "repurpose" major market drugs ... opens the door to the development of hundreds ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... S.A., a,French drug and diagnostic discovery company, today announces ... 2007., 2007 Key Events, - Milestone reached ... AGN ) in view of the initiation of Phase ... - Approval by the AFSSAPS (Agence Francaise de ...
... Germany, March 5 In mid-March the German,Bundestag (Lower ... the German Stem,Cell Act. The opposing poles in the ... apart: its proponents are calling for the complete,liberalisation of ... of a,general ban on the use of human stem ...
... Statins Alone, in Decreasing Cardiovascular Events in Diabetics with Haptoglobin ... ... March 5 Synvista,Therapeutics, Inc. (Amex: SYI ) announces the publication ... E to statin therapy prevented more cardiovascular events (heart,attack, stroke and cardiovascular ...
Cached Biology Technology:ExonHit Therapeutics - 2007 Financial Results 2ExonHit Therapeutics - 2007 Financial Results 3ExonHit Therapeutics - 2007 Financial Results 4ExonHit Therapeutics - 2007 Financial Results 5ExonHit Therapeutics - 2007 Financial Results 6ExonHit Therapeutics - 2007 Financial Results 7ExonHit Therapeutics - 2007 Financial Results 8ExonHit Therapeutics - 2007 Financial Results 9ExonHit Therapeutics - 2007 Financial Results 10ExonHit Therapeutics - 2007 Financial Results 11ExonHit Therapeutics - 2007 Financial Results 12A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 2Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 4
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... (November 4, 2014) — Think about the way our ... do neighboring cells know that they are supposed to ... do these tissues find the correct place and alignment? ... these crucial questions. , In a new study, UM ... communicate with their surrounding neighbors, at the head-trunk region. ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... diabetes during pregnancy is directly controlled by serotonin, a ... a neurotransmitter, and is influenced by the amount of ... to new findings of an international team led by ... to simple dietary solutions and possible therapeutics for the ...
... rich? Smithsonian researchers have new evidence that the answer ... to a study published in the journal, Nature ., ... not grow and survive well under their mothers or other ... fellow at the University of WisconsinMilwaukee and the Smithsonian Tropical ...
... available in Spanish . , At a time ... Service (ARS)-funded scientists have contributed to a limited but growing ... cognitive function. Cognitive function is measured by the ... use available information for activities of daily life. Alzheimer,s disease, ...
Cached Biology News:Gestational diabetes linked to serotonin and dietary protein 2Gestational diabetes linked to serotonin and dietary protein 3Biodiversity's holy grail is in the soil 2Vitamin D and mental agility in elders 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Viruses microRNA Microarray ...
Biology Products: